H ypertrophic cardiomyopathy (HCM) is the most commonly inherited monogenic cardiac disease with an estimated prevalence of 1:500.
Phenotypic-Genotypic Correlation by CMR in HCM
Although several small studies showed that MYBPC3 gene mutations were associated with a more benign course and a later onset, other studies failed to show this association. 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] CMR enables 3-dimensional tomographic assessment of cardiac anatomy and is considered the gold noninvasive standard for the evaluation of LV mass, volumes, and ejection fraction (LVEF). Additionally, LGE has the unique ability to identify areas of fibrosis. 23, 24 Scarce data exist on the genotype-phenotype association in patients with HCM as assessed by CMR. 25 We sought to compare CMR phenotype between patients harboring mutations in the 2 most common genes, MYH7 and MYBPC3.
Methods

Patient Selection
CMR was performed on 358 consecutive genotyped HCM probands who were enrolled as part of the multicenter registry involving 5 tertiary HCM centers in North America and Europe between November 2001 and February 2010. 26 HCM diagnosis was defined as a hypertrophied and nondilated LV (wall thickness ≥15 mm) in the absence of another cardiac or systemic disease expected to produce a similar magnitude of hypertrophy. 27, 28 Only patients with a single pathogenic mutation in either MYBPC3 or MYH7 genes were included in the analysis. All patients gave informed consent before undergoing genetic testing. The study was approved by the Research Ethics Board at each respective institution.
Genotype
Genetic testing for HCM comprised a combination of commercially available panels, including oligonucleotide hybridization-based DNA sequencing and dideoxy-based DNA sequencing. Testing initiated after February 2008 assessed 8 HCM-associated myofilament-encoding genes, involving MYBPC3, MYH7, essential and regulatory myosin light chains, cardiac troponin T, cardiac troponin I, α-tropomyosin, and cardiac actin, as well as 3 genes associated with metabolic cardiomyopathies: GLA for Fabry disease, LAMP2 for Danon disease, and PRKAG2 for PRKAG2 cardiomyopathy. Testing initiated before February 2008 did not include the GLA gene, and testing was initiated only in the setting of a clinical presentation suggestive of Fabry disease. Gene variants detected by genetic testing that were classified as pathogenic or presumed pathogenic were considered disease causing (positive genotype). Variant pathogenicity was confirmed based on a central validation of mutations by a genetic counselor according to the most updated American College of Medical Genetics and Genomics standards and guidelines. 29 These determinations were derived from a combination of factors, which may have included absence in control chromosomes, presence in unrelated probands, in silico predictions, conservation across species, and segregation analysis. Variants of unknown significance were classified as a negative genotype because of ambiguity with respect to their pathogenic role (Table I in 
CMR Analysis
CMR imaging was performed with a 1.5-T scanner using steady-state, free-precession breath-hold cines in 3 long-axis planes and sequential short-axis slices from the atrioventricular ring to the LV apex. LGE CMR imaging was performed 10 to 15 minutes after injection of 0.2 mmol/kg of gadolinium-diethylenetriaminepentaacetic acid with 2-dimensional segmented inversion recovery. Images from all centers were transferred to a core laboratory (PERFUSE, Boston, MA) for central, blinded analysis. LV volume, mass, and LVEF were measured by use of standard volumetric techniques and analyzed with commercially available software (QMASS version 7.4; Medis, Inc). LV endocardial and epicardial borders on cine images were manually planimetered to define the myocardium, taking care to exclude papillary muscles and the intertrabecular blood pool. Maximal LV wall thickness was defined as the greatest dimension at any site within the LV myocardium. LV chamber was assessed according to the American Heart Association 17-segment model. 30 LGE was defined quantitatively by a myocardial postcontrast signal intensity 6 SD above that within a reference region of remote myocardium (without LGE) within the same slice and by visual assessment. 31, 32 Regions with LGE were planimetered semiautomatically using QMASS 7.4 software. Total LGE mass was calculated by summing planimetered LGE areas and expressed as a proportion of LV myocardium (%LGE).
Anterior mitral leaflet and posterior mitral leaflet lengths were measured in diastole in the 3-chamber view as described by Maron et al. 33 
Statistical Analysis
Data are presented as mean±SD for normally distributed variables and as median (interquartile range) for non-normally distributed variables. Continuous variables were compared using Student t testing or Mann-Whitney testing, as appropriate. Categorical variables were compared using χ 2 statistics or Fischer exact testing, as appropriate. Cumulative event rates for outcomes including sudden death/appropriate shock, septal reduction, atrial fibrillation, and LVEF <50% were estimated using the Kaplan-Meier method and compared using log-rank statistics.
All tests were 2-tailed, with a P<0.05 considered significant. Statistical analysis was performed using SAS for Windows (version 9.3; SAS, Cary, NC).
Results
Patients' Baseline Characteristics
Genetic testing revealed a pathogenic mutation in 159 patients (44.4%). The most common genes were MYH7 (n=53) and MYBPC3 (n=75); 33.1% and 47% of genopositive patients, respectively. Table 1 describes the patients' baseline characteristics, which were similar with the exception of the proportion of men among patients with MYBPC3 mutations being significantly greater than among patients with MYH7 gene mutations (65% versus 40%; P=0.004). The risk profile for sudden cardiac death (SCD) was similar between the 2 groups. Table 2 depicts the CMR findings of patients with MYH7 gene mutation versus MYBPC3 gene mutation. Both groups had similar LV volumes, mass, LVEF, and maximal wall thickness. The distribution of the different morphologies (reversed curvature, neutral, sigmoid, and apical) was also similar. The presence of LGE was similar in patients with MYH7 gene mutation as compared with patients with MYBPC3 gene mutation (65% versus 64%, P=0.99). There was no significant difference in LGE burden, when quantified either as absolute mass or indexed as percentage of LV mass.
CMR Findings
Of note, in a subanalysis of patients aged ≥40 years (n=77), LVEF was lower in patients with MYBPC3 gene mutations (n=45) as compared with MYH7 gene mutations (n=32; 61.3% versus 65.5%, P=0.046). However, in contrast, there was no significant difference in quantified LGE in the 2 groups.
Outcomes
During a median follow-up time of 23.5 months (interquartile range, 14-36 months) there were no significant differences in outcomes between patients with MYH7 and MYBPC3 gene mutations including SCD (3.7% versus 1.3%; log-rank P=NS), septal reduction (13.2% versus 5.3%; log-rank P=NS), LVEF <50% (3.8% versus 6.7%; log-rank P=NS), and atrial fibrillation (16.9% versus 18.7%; log-rank P=NS; Figures I and II in the Data Supplement).
Thin Filaments
In exploratory analyses, we examined the 31 patients with pathogenic thin-filament gene mutations. This group of patients when compared with patients with mutations in MYBPC3 and MYH7 genes had a significantly lower prevalence of LV outflow tract obstruction (32.2% versus 53.1%; P=0.045) and family history of SCD (9.7% versus 32.8%; P=0.01; Table II in the Data Supplement). On CMR, those patients harboring thin-filament gene mutations had a significantly lower LVEF, yet still in the normal range (59.6% versus 64.7%; P=0.007), with a higher indexed LV end-systolic volumes (35.7 versus 29 mL/m 2 ; P=0.036). Notably, there were no significant differences in the presence and proportion of LGE, magnitude of LVH, indexed LV mass, and morphology subtypes between patients with thick and thin-filament gene mutations (Table III in 
Discussion
This is the largest study to date that compares the CMR phenotypic characteristics among HCM patients carrying the MYH7 and MYBPC3 gene mutations. In ≈45% of our cohort, similar to previous studies, genetic testing revealed a pathogenic mutation. 13, 14, 34, 35 The most common variants were detected in the MYBPC3 gene followed by MYH7 gene, together accounting for more than 3 quarters of HCM variants detected. In contrast to the MYH7 gene, where most mutations were missense mutations, about two thirds of mutations in the MYBPC3 gene were frameshift mutations or mutations that result in premature stop codons and in-frame insertions or deletions or that affect splicing. This is consistent with other HCM cohorts. 13, 18 We have found no differences in phenotype between patients with MYH7 and MYBPC3 gene mutations. Specifically, there were no significant differences in LV, mitral valve or left atrium parameters. BSA indicates body surface area; HCM, hypertrophic cardiomyopathy; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; and SCD, sudden cardiac death.
*Obstructive HCM was defined as left ventricular outflow tract gradient ≥30 mm Hg at rest or postprovocation on echocardiography.
†Nonsustained ventricular tachycardia was defined as ≥3 beats at ≥ 120 bpm. Most previous studies have suggested that patients with identified sarcomere mutations have more severe disease. 6, 35 A recent study by Rubinshtein et al 36 (n=245) found that LGE by contrast-enhanced magnetic resonance imaging was more common (75%) in patients with a positive genetic test compared with those (53%) with a negative genetic test (P=0.001). Yet, studies scrutinizing the relationship between the different genes and clinical phenotype provide conflicting results (Table IV in the Data Supplement). A recent study by Ellims et al 25 comparing only 17 patients with MYBPC3 gene mutations and 11 patients with MYH7 gene mutations found no significant differences in LV dimensions, volumes, maximal wall thickness, and LGE burden. We have confirmed their findings in a much larger cohort. A recent meta-analysis found no difference in the clinical expression between the 2 genes in terms of age at presentation, family history of SCD, and severity of LVH. 6 In contrast, a German-wide multicenter study of 97 genopositive patients with HCM and 69 genopositive patients with dilated cardiomyopathy found that patients with MYBPC3 gene mutations (n=52) had a higher mean interventricular septal wall thickness when compared with patients with MYH7 gene mutations (n=35). Interestingly, the study showed that both MYH7 and MYBPC3 gene mutations were associated with left atrial dilatation compared with genonegative patients; patients with MYBPC3 gene mutations had larger atrial sizes compared with those with MYH7 gene mutations. 13 This is in concordance with the present findings; the average indexed left atrial volume among patients with either mutation was higher than the normal reported values. 37 However, we found no difference in left atrial volume between the 2 genes.
We found no significant differences in clinical outcomes between patients with MYH7 gene mutations versus MYBPC3 gene mutations. However, it is noteworthy that the study included few outcomes and hence may be underpowered to detect significant differences in outcomes between the groups.
In the present study, we found no significant difference in LVEF between patients with MYBPC3 gene mutations when compared with MYH7 gene mutations. However, in patients ≥40 years of age, those with MYBPC3 gene mutations had significantly lower LVEF than those with MYH7 gene mutations. Our findings are consistent with a small study involving 27 patients with a founder mutation in MYBPC3 gene wherein 6 patients (22%) developed LV dysfunction (LVEF <50%) after the fourth decade. Notably, 2 of these developed LV dilatation with LV wall thinning. 38 Whether these differences in LV systolic function between patients with MYBPC3 and MYH7 gene mutations after the age of 40 years are indeed of significance will need further study.
Scarce data exist on differences in the presence and burden of myocardial fibrosis between patients harboring MYBPC3 and MYH7 gene mutations. We have detected similar prevalence and extent of myocardial fibrosis in genotyped patients with HCM irrespective of the involved gene (ie, MYH7 versus MYBPC3). These findings are consistent with a previous small sample sized study by Ellims et al, 25 of 28 patients (17 with MYBPC3 gene mutations and 11 with MYH7 gene mutations). In their study, in addition to LGE, T1 mapping did not differ between patients with MYBPC3 and MYH7 gene mutations. Furthermore, Olivotto et al 39 have recently shown no significant difference in the average myocardial blood flow after infusion of dipyridamole between patients with MYH7 and MYBPC3 gene mutations. Of note, they did not compare the prevalence and extent of myocardial fibrosis between the 2 groups. However, myocardial fibrosis is believed to result from bursts of silent and recurrent microvascular ischemia. 40, 41 Interestingly, the cells involved in the process of microvascular remodeling are not known to express any of the sarcomere proteins mutated in HCM. 42 Hence, a direct effect of the mutated proteins on the microvascular remodeling process has not been demonstrated to date. It is possible that the remodeling process occurs as a response to other changes caused by the mutated proteins or that the abnormality of the developmental process of the microvasculature is present in HCM. 42 Elongation of the mitral valve leaflets has been previously documented in gene-positive patients irrespective of LVH. 33 However, there have been no studies that have examined the variability in mitral valve leaflet lengths among the specific gene mutations. We have shown that there was no difference in both anterior and posterior mitral valve leaflet lengths between MYH7 and MYBPC3 gene mutations. The lack of differences in mitral valve leaflet length, severity of LVH, and type of septal morphology may account for the similar prevalence of LV outflow tract obstruction in the 2 groups.
Notably, in explanatory analyses, we have also observed no significant structural differences between patients harboring a thick versus thin-filament gene mutation, including maximal wall thickness and LV mass, presence and magnitude of LGE, and morphology subtypes. Although the mean LVEF of patients with thin-filament gene mutations was significantly lower than that of patients with thick-filament gene mutations, this was still in the normal range and hence should not have clinical implications. It is noteworthy that a recent study by Coppini et al 7 comparing the clinical phenotype and outcomes of 80 and 150 patients with thin and thick-filament gene mutations, respectively, found that patients with thinfilament gene mutations had a higher likelihood of advanced LV dysfunction and heart failure. In a subset of patients who had a CMR (≈60% of patients) those with thin-filament mutations had a lower LVEF. However, in contrast to our findings, patients with thin-filament gene mutations had a smaller LV mass index and greater LGE burden compared with patients with thick-filament gene mutation. 7 The lack of phenotypic differences between the different genes and the great variability in clinical HCM expression even among families sharing identical mutations suggest that there are other epigenetic factors in addition to the disease-causing mutation, which affect phenotypic expression. Accordingly, in the era of whole-genome analysis, assessment of phenotypic expression may require analysis beyond single gene mutations, which may provide novel insight into the pathogenesis of the disorder. Modifier genes, which are neither necessary nor sufficient to cause the HCM phenotype, seem to exert an important role in HCM and affect disease expression. Several studies have demonstrated the role of the renin-angiotensinaldosterone system in modifying the phenotype in HCM.
Ortlepp et al 43 have shown that genetic polymorphisms of the renin-angiotensin-aldosterone system influence Phenotypic-Genotypic Correlation by CMR in HCM penetrance and degree of LVH in 26 patients from a single family with HCM caused by a MYBPC3 mutation. Perkins et al 44 studied the role of 5 different renin-angiotensin-aldosterone system polymorphism genotypes in a cohort of 389 unrelated HCM patients genotyped for HCM-causing mutations in 8 sarcomeric/myofilament genes. They have demonstrated that renin-angiotensin-aldosterone system genotypes may modify the clinical phenotype of HCM in a disease genespecific fashion rather than indiscriminately, where significant pro-LVH effect of deletion/deletion in the angiotensin-converting enzyme was present only in patients with MYBPC3 HCM. In a South Indian HCM cohort, Rangaraju et al 45 have found genetic variants in angiotensin-converting enzyme, heat shock protein, and tumor necrosis factor-α genes to be associated with increased LVH, LV outflow tract obstruction, and clinical symptoms. Another study by Wang et al 46 on a Chinese cohort of HCM patients has identified a correlation between rs2106809 polymorphism of angiotensin-converting enzyme-2 gene allele and LVH in male patients. Additionally, Brugada et al 47 have shown increased hypertrophy in HCM patients carrying endothelin-1 gene variants. Because HCM is more common among males, Lind et al 48 investigated whether an association exists between genetic variation in sex hormone receptors and the development of LVH in HCM. They have illustrated that variation at the androgen receptor gene is associated with LVH in men with HCM.
The identification of the disease-causing mutations in the sarcomere genes 2 decades ago have brought with it great hope that identification of a disease causative mutation in an individual could be used as a clinical tool for prediction of disease severity and risk stratification for SCD. However, our findings demonstrate that currently available genetic testing, which includes genes known to cause HCM, may provide only limited additional clinical information. In this study, there were only limited (if any) phenotypic differences between the 2 most commonly found genes. Although the study was underpowered to detect differences in outcomes given the low event rates, there do not seem to be any meaningful trends in event rates that may translate into significant differences in larger populations. Therefore, at present, information from genetic testing may not contribute significantly to risk stratification or alter clinical management in the majority of patients with HCM. Yet, it plays a pivotal role in HCM as it helps to confirm a molecular diagnosis in the proband and is an invaluable tool in cascade screening of at-risk family members.
27,28
Limitations
Our study did not assess differences in penetrance among patients harboring MYH7 and MYBPC3 gene mutations as it included only patients who also had HCM phenotype. Second, we did not assess for modifier genes because only a few have been identified thus far. Finally, only patients who were able to undergo a CMR imaging were included; individuals with an implantable cardioverter defibrillator were not part of the analysis. Thus, we cannot exclude potential for selection bias.
Conclusions
The present study shows lack of differences in cardiac morphology between MYH7 and MYBPC3 gene mutations as assessed by CMR. Although identification of the specific thick-filament mutation does not seem to provide additional clinical information in HCM patients, detecting pathogenic gene variants remains useful in confirmation of diagnosis and cascade screening.
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